Capital Markets Update
2026

investor

Nova Biomedical

Byron Selman
CEO

NOVA BIOMEDICAL®

Advancing healthcare through critical measurement



WHO WE ARE

Nova Biomedical delivers decision-critical data for healthcare

OUR VISION

Improve the health of every patient through innovation and excellence.

OUR VALUES

Customer Centricity • Ingenuity • Ownership & Accountability • Collaboration • Integrity

SCIENTIFIC AND ANALYTICAL SOLUTIONS FROM DRUG DEVELOPMENT THROUGH PATIENT CARE



VACCINE DEVELOPMENT



VACCINE MANUFACTURING



HOSPITAL LAB TESTING



PATIENT TESTING AT BEDSIDE



PATIENT TREATMENT DECISIONS



PATIENT CARE

BETTER DATA → BETTER OUTCOMES

Strong track record of profitable growth	$72M → $702M	~35%	5
	GROWTH SINCE 2020 PI ACQUISITION	LTM EBITDA MARGINS	TECHNOLOGY ACQUISITIONS

NOVA BIOMEDICAL®



Culture of continuous innovation

500,000+

Systems installed globally

Top 10

Biopharma customers and numerous leading health care institutions

Why we are well-positioned for sustainable growth

Attractive end-markets

Biopharma and Clinical

Innovation pipeline

10 new products in 3 years

Market leadership

Trusted brands

Global commercial reach

Direct sales in key markets

Recurring revenue model

Customer support

Proven management team

Decades of experience

Balanced end-markets and global reach

END-MARKET REVENUE MIX



66% Clinical

34% Biopharma

GEOGRAPHIC REVENUE MIX



60% NA


24% EU

16% ROW

OUR STORY

Decades of innovation-driven growth

Two pioneers, one turning point: Patricia Industries ownership accelerated innovation, acquisitions, and global scale.



THE MARKETS WE SERVE

Two attractive markets representing >$22B in opportunity

Biopharma

~$12B
2026 EST.
ANALYTICS MARKET

~6%
EST. MARKET CAGR

MARKET TREND	HOW NOVA SOLVES IT
More complex therapies	**VIPS PRO + OsmoTECH + BioProfile FLEX2** Systems to select and measure the most potent cells for vaccine development
Shorter development timelines	**FLEX2 + Artel** Systems that run rapid test providing real time results
Regulated workflows	**STUDIUS + GMP-certified consumables** Meets all regulatory requirements

CUSTOMERS SERVED Biopharma companies, CDMOs, and CROs across cell and gene therapy

Clinical

~$10B
2026 EST.
SERVED MARKET

~4%
EST. MARKET CAGR

MARKET TREND	HOW NOVA SOLVES IT
Staffing and workload pressure	**Prime family + OsmoPRO MAX** Maintenance-free automated systems
Testing closer to the patient	**StatStrip + Prime family** Patient bedside testing
Hospital capacity pressure	**Prime family** Multiple measurements within 90 sec

CUSTOMERS SERVED Hospitals, academic medical centers, reference labs, and outpatient settings.

BIOPHARMA

Innovation in biologics is moving faster than any time in history

SCIENTIFIC ADVANCES IN RECENT YEARS

First cancer vaccine clears a major trial

An mRNA vaccine was the first vaccine to slow cancer (melanoma) from spreading and coming back.

CNN / STAT News · Aug 2026

Moving from treating symptoms to treating disease

First FDA approved therapy addressing the underlying cause of Alzheimer's disease

NEJM · 2025

Years drug-free after a single treatment

One cellular therapy infusion put Lupus patients into lasting remission.

STAT News · 2026

NOVA'S BIOPHARMA PORTFOLIO PROVIDES CRITICAL DATA TO ENABLE BIOPHARMA R&D AND PRODUCTION

Which cell do we pick?

CONTROL POINT: CELL LINE DEVELOPMENT

Will it work in a larger batch?

CONTROL POINT: PROCESS DEVELOPMENT

Is this batch maintaining optimal quality?

CONTROL POINT: MANUFACTURING

NOVA BIOMEDICAL®

WHAT WE DO

Nova provides the tools and data that scientists need to move biopharma products forward more quickly and more effectively

Biopharma

Providing critical data in vaccine production

Nova Systems Help Customers Make Critical Decisions Across the Workflow

- Cell Selection: Solentim and NanoCellect select cells with the highest potential.
- Process Development: Bioprofile and OsmoTECH optimize processes for best results.
- Pilot + scale: Artel and OsmoTECH prove the process works as production scales.
- Manufacture + QC: OsmoTECH helps maintain quality levels batch after batch.



SELECT THE MOST POTENT CELLS

Solentim + NanoCellect



DEVELOP THE MANUFACTURING LINE

BioProfile + OsmoTECH



RAMP UP PRODUCTION

Artel + OsmoTECH



MANUFACTURE + QC

OsmoTECH

CLINICAL

Nova's clinical diagnostic products enable rapid and accurate results that inform critical patient treatment decisions in the hospital

WHAT HOSPITALS NEED	THE ADVANTAGE IS WON HERE
Testing at the patient bedside Testing at the "point of care" enables quick action	**Rapid Patient Diagnosis** Systems that are portable, hand-held, and provide rapid and accurate results, such as glucose levels, inform immediate treatment and ongoing patient management.
Differentiation matters Hospitals require proven accuracy and meaningful results	**Trusted and Differentiated Results** Proven accuracy and differentiated clinical claims supporting diagnosis and treatment for disease states such as diabetes and electrolyte imbalance.
Connected workflows are becoming essential Control across devices, operators, quality, and results.	**Connected Clinical Workflows** Devices, users, quality processes, and results connected across the hospital.

Nova is positioned in durable clinical workflows where essential tests, differentiated performance, and connectivity create value beyond cost per test.

NOVA BIOMEDICAL®

WHAT WE DO

Nova's instruments provide the data physicians rely on to make critical treatment decisions and enable connected disease-state solutions in hospitals

Clinical

Trusted in the moments that shape patient care.

Critical Points of Care

- Point of care: testing at or near the bedside.
- Hospital lab: diagnosis and monitoring.
- Outpatient Clinics: testing outside the hospital lab.
- Data Connectivity: one view access to key data



TEST AT PATIENT BEDSIDE

StatStrip Glucometer



TEST AT HOSPITAL LABS

OsmoPRO MAX



TESTING OUTSIDE THE HOSPITAL

Nova Max Pro



CONNECT + INFORM TREATMENT

NovaNet

INNOVATION — HOW WE CREATE VALUE

Advanced core technologies, an AI-enabled R&D engine, and a roadmap that scales today's strengths while building tomorrow's platforms

CORE TECHNOLOGIES → PRODUCTS

Chemistry
StatStrip · Stat Profile Prime



Microfluidics
GloCyte · NanoCellect



Optics
Stat Profile Prime+ · Artel MVS



Imaging
VIPS PRO · Cell Metric X



Analytics & AI
STUDIUS · NovaNet



Critical data access
NovaNet · ArtelWare



THE R&D ENGINE
Shared knowledge & data · AI-enabled R&D · Integration execution · Targeted strategic acquisition



INNOVATION ROADMAP



Build on our time-tested, proven products

Biosensing, cell analysis, osmometry, and analytics customers already rely on.

Stat Profile Prime · BioProfile FLEX2 · OsmoTECH PRO



Leverage our growing toolbox of core technologies

Expand features, quality, and cost — and carry current technology into new products.

StatStrip · OsmoTECH HT · Artel MVS



Develop platform and modular designs

Shared platforms and modular sub-systems reused across product families.

Shared freeze engine · Common sensor architecture



Create the next disruptive innovations

An AI-enabled R&D operating system delivering game-changing technologies.

STUDIUS · NanoCellect

NOVA BIOMEDICAL®

ARTIFICIAL INTELLIGENCE STRATEGY & VISION

Compounding value through AI leadership

AREAS OF FOCUS



STRATEGIC GROWTH AREAS

PRODUCT

Improve how our products perform through predictive analytics

CUSTOMER

Improve the customer experience by anticipating instrument service needs

EMPLOYEES

Improve how our teams work by automating routine tasks

ENTERPRISE DATA FOUNDATION

One shared data foundation

Shared context for every agent and sub-agent — compounding insights with every use.


UNIQUE DATA REACH · FROM THE PRODUCTION LINE TO THE END CUSTOMER

Manufacturing → Quality & Regulatory → Products → Sales team → **CUSTOMERS**

NOVA BIOMEDICAL

FINANCIALS

Track record of strong organic and non-organic growth



THE NOVA OPPORTUNITY

Well-positioned for sustainable long-term profitable growth

Nova sits at the center of two growing healthcare markets, delivering critical, high-value measurements for customers

Two large and growing healthcare markets

More than $22B of combined market opportunity across biopharma and clinical

Attractive, consumables-driven business model

500,000+ systems installed and generating consumables, software, and service revenue

Innovative products delivering strong customer value

Differentiated, innovative products that provide customers the data to make critical decisions with confidence

Improving the health of every patient

BETTER INFORMATION → BETTER DECISIONS → BETTER OUTCOMES

Capital Markets Update 2026

investor